HemoSense to Present at the Lazard Capital Markets Third Annual Life Sciences Conference

  
    
  
  
    
      HemoSense, Inc. (AMEX:HEM) today announced that Jim Merselis, 
      President and CEO, will make an investment community presentation at the 
      Lazard Capital Markets Third Annual Life Sciences Conference on Tuesday, 
      November 28 at 2 p.m. Eastern time (11 a.m. Pacific time). The 
      conference is being held at The New York Palace Hotel, New York.
    
    
      A live audio and slide webcast of the presentation will be available via 
      the Internet by visiting the Investors section of the Company’s 
      Web site at www.hemosense.com. 
      An archived presentation will be available on the Web site for 30 days.
    
    
      About HemoSense
    
    
      HemoSense develops, manufactures and markets easy-to-use, handheld blood 
      coagulation systems for monitoring patients taking warfarin. The 
      HemoSense INRatio® system, used by healthcare 
      professionals and patients themselves, consists of a small monitor and 
      disposable test strips. It provides accurate and convenient measurement 
      of blood clotting time, or PT/INR values. Routine measurements of PT/INR 
      are necessary for the safe and effective management of the patient’s 
      warfarin dosing. INRatio is sold in the United States and 
      internationally. For more information, visit www.hemosense.com.
    
    
      HemoSense® and INRatio® 
      are registered trademarks of HemoSense, Inc.
    
  
HemoSense, Inc. (AMEX:HEM) today announced that Jim Merselis,
President and CEO, will make an investment community presentation at
the Lazard Capital Markets Third Annual Life Sciences Conference on
Tuesday, November 28 at 2 p.m. Eastern time (11 a.m. Pacific time).
The conference is being held at The New York Palace Hotel, New York.

   A live audio and slide webcast of the presentation will be
available via the Internet by visiting the Investors section of the
Company's Web site at www.hemosense.com. An archived presentation will
be available on the Web site for 30 days.

   About HemoSense

   HemoSense develops, manufactures and markets easy-to-use, handheld
blood coagulation systems for monitoring patients taking warfarin. The
HemoSense INRatio(R) system, used by healthcare professionals and
patients themselves, consists of a small monitor and disposable test
strips. It provides accurate and convenient measurement of blood
clotting time, or PT/INR values. Routine measurements of PT/INR are
necessary for the safe and effective management of the patient's
warfarin dosing. INRatio is sold in the United States and
internationally. For more information, visit www.hemosense.com.

   HemoSense(R) and INRatio(R) are registered trademarks of
HemoSense, Inc.